To Get Full Access :

Pombiliti

Pombiliti, used with Opfolda (miglustat), treats adults with late-onset Pompe disease who aren’t responding to enzyme replacement therapy. It delivers an enzyme to break down muscle-accumulated glycogen, improving muscle strength and lung function.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

  • Molecule Name :

    Cipaglucosidase Alfa-Atga
  • Innovator :

    AMICUS THERAPEUTICS
  • Approval Date :

    28-Sep-23
  • Data Exclusivity Expiry :

    28-Sep-27
  • Market Exclusivity Expiry :

    28-Sep-35
  • Dosage Form :

    IV Infusion
  • Strength :

    105mg/vial
  • Therapeutic Category :

    Antimetabolic Disorder
  • Revenue ($M) :

    113

Year-wise Projected Sales ($M) :

  • 2026 :

    NA
  • 2027 :

    NA
  • 2028 :

    NA
  • 2029 :

    NA
  • 2030 :

    NA
  • 2031 :

    NA
  • 2032 :

    NA
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?